G. Caramori (Ferrara, Italy), G. Anderson (Parkville, Australia)
Effect of carmoterol PMDI on 24-hour FEV1 in COPD patients
D. Tashkin, E. Kleerup, E. Heyman, D. Norris, S. Petruzzelli (Los Angeles, Rockville, United States Of America; Parma, Italy)
|   |
Qva149, a novel combination of indacaterol and glycopyrronium, demonstrates superior bronchodilation compared with indacaterol or placebo in patients with COPD
J. A. van Noord, R. Buhl, C. LaForce, C. Martin, F. Jones, M. Dolker, T. Overend (Heerlen, Netherlands; Mainz, Germany; Raleigh, East Hanover, United States Of America; Horsham, United Kingdom)
| |
Protective effects of salmeterol on impeded alveolar-capillary gas transfer with saline infusion in COPD patients: preliminary results
F. Di Marco, M. Guazzi, G. F. Sferrazza Papa, M. Vicenzi, M. Felice Civitillo, P. Santus, P. Busatto, S. Centanni (Milan, Italy)
| |
Single dose budesonide/carmoterol fixed combination improves lung function over 24 hours in patients with moderate to severe persistent asthma
A. Woodcock, M. A. Nandeuil, H. Raptis, M. Costantini, S. Petruzzelli, D. Singh (Manchester, United Kingdom; Courbevoie, France; Parma, Italy)
| |
Bronchodilator therapy with indacaterol once-daily in COPD: a 52-week comparison with formoterol
R. Dahl, P. Kolman, D. Jack, P. Bleasdale, R. Owen, M. Higgins, B. Kramer (Aarhus, Denmark; Kyjov, Czech Republic; West Sussex, United Kingdom; East Hanover, United States Of America)
| |
ACCLaim/COPD II: efficacy and safety of aclidinium bromide, a novel, long-acting muscarinic antagonist in COPD patients, a phase III study
S. Rennard, J. Donohue, E. Bateman, N. Gross, E. Garcia Gil, C. Caracta (Omaha, Chapel Hill, Hines, Jersey City, United States Of America; Cape Town, South Africa; Barcelona, Spain)
| |
Utility of high dose inhaled fluticasone therapy for the early management of acute exacerbations of asthma
S. K. Agarwal, N. Arshad (Varanasi, Gorakhpur, India)
| |
Acute bronchodilator response does not predict health outcomes in patients with COPD treated with tiotropium
N. Hanania, S. Kesten, B. Celli, M. Decramer, A. Sharafkhaneh, T. Lystig, S. Mehra, D. Tashkin (Houston, Ridgefield, Boston, New York, Los Angeles, United States Of America; Leuven, Belgium)
| |
Pharmacokinetics of PF-00610355, a novel inhaled long-acting β2-adrenoreceptor agonist
G. L. Li, F. MacIntyre, B. Surujbally, C. L. Chong, J. Davis (Sandwich, United Kingdom; Singapore, Singapore)
| |
A randomised double-blind, study to determine the efficacy & safety of a once-daily inhaled β2 adrenoreceptor agonist, PF-00610355 in asthmatic patients
J. Ward, F. Macintyre, I. Jones, B. Surujbally, D. Scholl, E. Bateman (Sandwich, United Kingdom; Cape Town, South Africa)
| |
Efficacy and safety of indacaterol 150 μg once-daily in COPD: a 12-week study
G. Feldman, T. Siler, N. Prasad, S. Piggott, R. Owen, M. Higgins, B. Kramer (Spartanburg, St. Charles, East Hanover, United States Of America; West Sussex, United Kingdom)
| |
Effect of indacaterol maleate on dynamic lung hyperinflation in patients with COPD
K. M. Beeh, S. Khindri, M. Eeg, A. F. Drollmann (Weisbaden, Germany; West Sussex, United Kingdom)
| |
Indacaterol dose selection: utilising an adaptive seamless design in a clinical study in COPD
P. J. Barnes, S. J. Pocock, H. Magnussen, A. Iqbal, B. Kramer, M. Higgins, D. Lawrence (London, West Sussex, United Kingdom; Grosshansdorf, Germany; East Hanover, United States Of America)
| |
Safety and tolerability of indacaterol over 52 weeks of treatment in COPD
F. Chung, O. Kornmann, D. Jack, R. Owen, B. Kramer, M. Higgins (London, West Sussex, United Kingdom; Mainz, Germany; East Hanover, United States Of America)
| |
Indacaterol once-daily improves dyspnoea in COPD patients: a 26-week placebo-controlled study with open-label tiotropium comparison
D. Mahler, P. Palange, A. Iqbal, R. Owen, M. Higgins, B. Kramer (New Hampshire, East Hanover, United States Of America; Rome, Italy; Horsham, United Kingdom)
| |
Indacaterol once-daily is equally effective dosed either in the evening or morning in COPD patients
H. Magnussen, C. Verkindre, D. Jack, D. Jadayel, R. Owen, M. Higgins, B. Kramer (Grosshansdorf, Germany; Beuvry, France; Horsham, United Kingdom; East Hanover, United States Of America)
| |
Rate of onset of action of aclidinium bromide, a novel, long-acting, muscarinic antagonist
J. Vestbo, C. Vogelmeier, J. Creemers, A. Ribera, E. Garcia Gil (Manchester, United Kingdom; Marburg, Germany; Eindhoven, Netherlands; Barcelona, Spain)
| |
Fast onset of bronchodilation with indacaterol in patients with COPD
B. Balint, H. Watz, C. Amos, R. Owen, B. Kramer, M. Higgins (Deszk, Hungary; Grosshansdorf, Germany; Horsham, United Kingdom; East Hanover, United States Of America)
| |
Effects of tiotropium on neurohumoral activation during exercise in stable COPD patients
K. Yoshimura, T. Hiraga, S. Kitada, Y. Tateishi, R. Maekura (Toneyama, Japan)
| |
Safety and pharmacokinetics of aclidinium bromide, a novel, long-acting muscarinic antagonist, in renally impaired subjects
K. Schmid, S. Pascual, E. Garcia Gil, S. Ortiz, J. Maria Jansat (Munich, Germany; Barcelona, Spain; Jersey City, United States Of America)
| |